2022. Comparison between antineoplastic treatments with selective inhibitors (BRAF/MEK) and the new potentials combinatorial therapies for metastatic melanoma. Research, Society and Development. 11, 14 (Oct. 2022), e326111436275. DOI:https://doi.org/10.33448/rsd-v11i14.36275.